Recruiting
Phase 3

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Sponsor:

AstraZeneca

Code:

NCT06120491

Conditions

Metastatic Castration-Sensitive Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Saruparib

Placebo

Abiraterone Acetate

Darolutamide

Enzalutamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information